Get the Stockscreener App
15.44
4.36%
0.645
Oruka Therapeutics Inc stock is traded at $15.44, with a volume of 152.70K.
It is up +4.36% in the last 24 hours and up +9.78% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$14.79
Open:
$14.87
24h Volume:
152.70K
Relative Volume:
0.72
Market Cap:
$578.05M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.42%
1M Performance:
+9.78%
6M Performance:
+40.06%
1Y Performance:
+0.00%
1-Day Range:
$14.68
$15.81
1-Week Range:
$14.08
$15.81
52-Week Range:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
15.44 | 571.12M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Clear Street initiates Oruka Therapeutics stock with Buy rating on psoriasis drugs - Investing.com
Technical analysis overview for Oruka Therapeutics Inc. stockOil Prices & High Yield Stock Recommendations - Newser
What to expect from Oruka Therapeutics Inc. in the next 30 daysMarket Trend Summary & Reliable Entry Point Trade Alerts - Newser
Support Zone Holds Steady for Oruka Therapeutics Inc. After DipGold Moves & Momentum Based Trading Ideas - beatles.ru
How to integrate Oruka Therapeutics Inc. into portfolio analysis toolsIndex Update & Fast Momentum Entry Tips - Newser
Oruka Therapeutics Inc.’s volatility index tracking explainedMarket Performance Recap & Fast Exit and Entry Strategy Plans - Newser
Will Oruka Therapeutics Inc. outperform the marketAnalyst Upgrade & Community Supported Trade Ideas - Newser
Oruka Therapeutics Inc. stock trendline breakdown2025 Price Targets & Free Long-Term Investment Growth Plans - Newser
Applying Wyckoff theory to Oruka Therapeutics Inc. stockJuly 2025 Retail & Safe Capital Investment Plans - Newser
Real time scanner hits for Oruka Therapeutics Inc. explained2025 Sector Review & Fast Moving Stock Watchlists - Newser
Applying Elliott Wave Theory to Oruka Therapeutics Inc.2025 Institutional Moves & AI Powered Market Trend Analysis - Newser
Statistical indicators supporting Oruka Therapeutics Inc.’s strengthJuly 2025 Technicals & Technical Pattern Alert System - Newser
Oruka Therapeutics Inc. Attempts Reversal From Key SupportJuly 2025 Price Swings & Weekly Top Gainers Alerts - beatles.ru
Oruka Therapeutics (NASDAQ:ORKA) Given “Buy” Rating at HC Wainwright - Defense World
Applying sector rotation models to Oruka Therapeutics Inc.Quarterly Market Summary & Expert Approved Momentum Ideas - Newser
Smart tools for monitoring Oruka Therapeutics Inc.’s price actionGap Down & Low Drawdown Momentum Ideas - Newser
Is Oruka Therapeutics Inc. a candidate for recovery play2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Has Oruka Therapeutics Inc. found a price floorJuly 2025 Opening Moves & AI Based Buy/Sell Signal Reports - Newser
Long term hold vs stop loss in Oruka Therapeutics Inc.Global Markets & Stepwise Trade Execution Plans - Newser
How high can Oruka Therapeutics Inc. stock price go in 2025Weekly Gains Report & Community Verified Trade Alerts - Newser
What Fibonacci levels say about Oruka Therapeutics Inc. reboundPortfolio Update Summary & Free Risk Controlled Daily Trade Plans - Newser
How to build a custom watchlist for Oruka Therapeutics Inc.2025 Bull vs Bear & Stock Timing and Entry Methods - Newser
What makes Oruka Therapeutics Inc. stock price move sharplyBear Alert & Daily Market Momentum Tracking - Newser
Oruka Therapeutics (NASDAQ:ORKA) Downgraded by Wall Street Zen to “Sell” - Defense World
Q3 EPS Estimates for Oruka Therapeutics Decreased by Wedbush - Defense World
Can technical indicators confirm Oruka Therapeutics Inc.’s reversalQuarterly Market Summary & Consistent Growth Stock Picks - Newser
Why Oruka Therapeutics Inc. stock attracts strong analyst attentionMarket Trend Report & Consistent Income Trade Ideas - Newser
Oruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
What is the Moat Score of Oruka Therapeutics Inc.Quarterly Performance Summary & Fast Momentum Stock Entry Tips - thegnnews.com
Leerink Partnrs Has Pessimistic View of ORKA Q3 Earnings - Defense World
Custom watchlist performance reports with Oruka Therapeutics Inc.Earnings Growth Report & Community Trade Idea Sharing - Newser
Published on: 2025-08-13 20:29:16 - beatles.ru
Oruka Therapeutics’ (ORKA) Outperform Rating Reaffirmed at Wedbush - Defense World
Oruka Therapeutics stock maintains Buy rating at BTIG on promising psoriasis treatments - Investing.com Canada
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):